Onyx Pharmaceuticals




News and Media        
Onyx Pharmaceuticals

PRESS RELEASES
--------
Press Releases

To Onyx's knowledge, all press releases, scientific papers, and abstracts and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. Onyx has no intention of updating this information, and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

Email Alerts

Sign up here to receive press releases via email.
  Submit



  • Nov. 22, 2004
Onyx Pharmaceuticals to Present at Lazard Life Sciences Conference
  • Nov. 04, 2004
Onyx Pharmaceuticals Reports Third Quarter and Nine Month 2004 Financial Results
  • Nov. 02, 2004
Bayer and Onyx Announce Results of Phase I Studies Evaluating BAY 43-9006 in Combination with Conventional Chemotherapy Drugs
  • Nov. 01, 2004
Onyx Pharmaceuticals Announce Third Quarter 2004 Financial Results Webcast and Teleconference
  • Oct. 27, 2004
FDA Grants Orphan Drug Designation to Bay 43-9006 for the Treatment of Renal Cell Carcinoma
  • Oct. 25, 2004
Bayer and Onyx Announce Positive Phase II Data in Patients with Advanced Kidney Cancer
  • Oct. 23, 2004
Onyx Pharmaceuticals Announces a Webcast and Teleconference to Provide an Update on BAY 43-9006
  • Sep. 29, 2004
Bayer and Onyx Announce Phase II Results of Treatment with Bay 43-9006 in Patients with Advanced Primary Liver Cancer
  • Sep. 21, 2004
Onyx Pharmaceuticals to Present at UBS Global Life Sciences Conference
  • Sep. 20, 2004
Onyx Pharmaceuticals Achieves Milestone in Cancer Program with Pfizer
  • Sep. 02, 2004
Onyx Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
  • Aug. 09, 2004
Onyx Pharmaceuticals Reports Second Quarter and Six Month 2004 Financial Results
  • Aug. 04, 2004
EMEA Grants Orphan Drug Designation to BAY 43-9006 for the Treatment of Renal Cell Carcinoma
  • Aug. 02, 2004
Onyx Pharmaceuticals Announces Second Quarter 2004 Financial Results Webcast and Teleconference
  • Jun. 09, 2004
Onyx Pharmaceuticals to Webcast June 15 Analyst Briefing
  • Jun. 07, 2004
Onyx Pharmaceuticals to Present at Upcoming Healthcare Conferences
  • Jun. 06, 2004
Encouraging Data on BAY 43-9006 in Combination with Standard Chemotherapeutics as Melanoma Treatment Presented at American Society of Clinical Oncology Meeting
  • Jun. 05, 2004
Encouraging Interim Results on BAY 43-9006 in Advanced Kidney Cancer Presented at American Society of Clinical Oncology (ASCO) Meeting
  • Jun. 03, 2004
Onxy Appoints Edward Kenney Executive Vice President and Chief Business Officer
  • May 13, 2004
Onyx Pharmaceuticals to Present at Bank of America Securities Health Care Conference
  • May 05, 2004
Onyx Pharmaceuticals Reports First Quarter 2004 Financial Results
  • Apr. 19, 2004
Onyx Pharmaceuticals to Present at Upcoming Conferences
  • Apr. 05, 2004
BAY 43-9006 Receives Fast Track Designation from the FDA for Metastatic Kidney Cancer Review
  • Feb. 26, 2004
Onyx Pharmaceuticals to Present at Upcoming Healthcare Conference
  • Feb. 18, 2004
Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
  • Feb. 12, 2004
Onyx Pharmaceuticals Reports Fourth Quarter and Year End 2003 Financial Results
  • Feb. 03, 2004
Onyx Announces Pricing of Common Stock in Public Offering
  • Jan. 26, 2004
Onyx Announces Public Offering of Common Stock




--------

©2008 Onyx Pharmaceuticals, Inc.